Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 701–800 of 1,001
Efficacy and Safety of Sitagliptin in the Treatment of Type 2 Diabetes
Gadsby, R. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2313 · Cited by 19
Incretins and the intensivist: what are they and what does an intensivist need to know about them?
Plummer, M. P., Chapman, M. J., Horowitz, M., & Deane, A. M. (2014) · Critical Care · doi:10.1186/cc13737 · Cited by 18
“Attenuation of the incretin effect and pathogenesis of hyperglycaemia in type 2 diabetes In 1986 Nauck and colleagues reported that the magnitude of the incretin effect was markedly diminished in longstanding T2DM [23], and they went on to show that the insulinotropic effect of GIP is also attenuated in this group, wh…”
BackgroundA siRNA mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice
Görgens, S. W., Jahn‐Hofmann, K., Bangari, D. S., Cummings, S., Metz-Weidmann, C., Schwahn, U., Wohlfart, P., Schäfer, M., & Bielohuby, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225835 · Cited by 16
Drug discovery approaches targeting the incretin pathway
Deng, X., Tavallaie, M. S., Sun, R., Wang, J., Cai, Q., Shen, J., Lei, S., Fu, L., & Jiang, F. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103810 · Cited by 15
Therapeutic Potential of Dipeptidyl Peptidase-IV Inhibitors in Patients With Diabetes Mellitus
Moore, K. B., & Saudek, C. D. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180ed42dc · Cited by 15
“In patients with type 2 diabetes, baseline GLP1 and GIP concentrations may be normal; GIP increases appropriately with food, whereas GLP-1 secretion is significantly impaired.(30,31) The impact of GLP-1 and GIP on insulin secretion is glucose-dependent; therefore, insulin secretion is only enhanced in the setting of e…”
BackgroundReview: DPP IV inhibitors - current evidence and future directions
Vilsbøll, T., & Knop, F. K. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070020401 · Cited by 17
Differentiating Incretin Therapies Based on Structure Activity, and Metabolism: Focus on Liraglutide
Grossman, S. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.25s · Cited by 16
“Early studies found that the incretin effect was decreased in patients with type 2 diabetes compared with healthy controls.(20) However, this could not be correlated with GIP levels in response to oral glucose, which were generally found to be similar to healthy controls.”
BackgroundGalderisi, A., Tricò, D., Pierpont, B. M., Shabanova, V., Samuels, S. L., Man, C. D., Galuppo, B., Santoro, N., & Caprio, S. (2020) · Diabetes Care · doi:10.2337/dc20-0445 · Cited by 19
Roges, O. A., Baron, M., & Philis‐Tsimikas, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.705 · Cited by 15
“Therefore, these patients are characterised by an impaired incretin effect, and as Type 2 diabetes is characterised by a decreased meal-stimulated insulin secretion, an impaired incretin action may contribute to the impaired insulin secretion [14,150].”
BackgroundHartmann, B., Longo, M., Mathiesen, D. S., Hare, K. J., Jørgensen, N. R., Esposito, K., Deacon, C. F., Vilsbøll, T., Holst, J. J., & Knop, F. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad431 · Cited by 14
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
Islet hormones at the intersection of glucose and amino acid metabolism
White, P. J., Albrechtsen, N. J. W., & Campbell, J. E. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01100-4 · Cited by 18
“This loss of incretin response explains some of the β-cell dysfunction that occurs with metabolic stress 66 .”
InfluentialUmapathysivam, M. M., Araldi, E., Hastoy, B., Dawed, A. Y., Vatandaslar, H., Mayrhofer, J. E., Lindquist, P., Silva, P. N., Goga, A., Trüllinger, G. O., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01630-0 · Cited by 15
Improved Glycemic Control Enhances the Incretin Effect in Patients With Type 2 Diabetes
An, Z., Prigeon, R. L., & D’Alessio, D. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1199 · Cited by 16
ŠEBÖKOVÁ, E., Benardeau, A. M., Sprecher, U., Sewing, S., Tobalina, L., & Migliorini, C. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01207.x · Cited by 15
“com 2 diabetes exhibit a reduced incretin effect [4], which is partially a consequence of reduced secretion of GLP-1 [5], although this defect may be an effect of the diabetic state rather than a cause [6].”
BackgroundPatel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Anti-obesity weight loss medications: Short-term and long-term use
Jeong, D., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120825 · Cited by 21
Maagensen, H., Helsted, M. M., Gasbjerg, L. S., Vilsbøll, T., & Knop, F. K. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00767-2 · Cited by 16
García‐Jiménez, C. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00014-x · Cited by 15
Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare, K. J. (2010) · PubMed · Cited by 18
Incretin hormones and beta cell function in chronic pancreatitis.
Knop, F. K. (2010) · PubMed · Cited by 17
Gastrointestinal hormones and polycystic ovary syndrome
Ma, J., Lin, T. C., & Liu, W. (2014) · Endocrine · doi:10.1007/s12020-014-0275-1 · Cited by 15
Regulation of Energy Homeostasis After Gastric Bypass Surgery
Yarmush, M. L., D'Alessandro, M. R., & Saeidi, N. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105140 · Cited by 17
Diabetes: the place of new therapies
Dhatariya, K. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818807599 · Cited by 14
Pathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 16
Insulin Secretion in Diabetes Mellitus
Cerasi, E. (1988) · Springer eBooks · doi:10.1007/978-3-642-72691-0_11 · Cited by 14
Understanding the Incretin Effect
Seino, Y. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0329 · Cited by 17
Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1295639 · Cited by 13
“People with obesity and/or T2D have impaired incretin release (Toft-Nielsen et al., 2001; Vilsbøll et al., 2001) and/or function (Nauck et al., 1986; Muscelli et al., 2008), and GLP-1-targeted therapies offer effective management of body weight and blood glucose levels, with underlying improvements…”
BackgroundRoell, W. C., Alsina‐Fernandez, J., Qu, H., Coşkun, T., Benson, C., Haupt, A., Kelly, R. P., O’Farrell, L. S., Sloop, K. W., Steele, J. P., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102298 · Cited by 13
Colonic L-cell impairment in aged subjects with type 2 diabetes leads to diminished GLP-1 production
Wang, Q., Zhang, W., Zhao, Y., Chen, H.-L., Liu, Q., Wang, Z., Zeng, L.-T., Li, J., Chen, S., Wei, L., et al. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102907 · Cited by 15
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes
Ryan, G. J., & Hardy, Y. M. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01180.x · Cited by 16
“GIP levels are normal in type 2 diabetes, but the response is defective (18, 31, 32).”
BackgroundAhmadi, S., Shahsavani, M. B., Tavaf, Z., Albaghlany, R. M., Kumar, A., Moosavi‐Movahedi, A. A., & Yousefi, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266833 · Cited by 13
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 22
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes
Wick, A., & Newlin, K. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00455.x · Cited by 13
Oh, T. J., Shin, J. Y., Kang, G. H., Park, K. S., & Cho, Y. M. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.58 · Cited by 13
Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin
Taldone, T., Zito, S. W., & Talele, T. T. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.107 · Cited by 13
Albiglutide for the management of type 2 diabetes
Rendell, M. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1419061 · Cited by 16
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., John‐Kalarickal, J., & Fonseca, V. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_13 · Cited by 15
Development of minimally invasive techniques for management of medically-complicated obesity
Rashti, F., Gupta, E., Ebrahimi, S., Shope, T. R., Koch, T. R., & Gostout, C. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13424 · Cited by 13
Johansson, A., Olsson, T., Cederquist, K., Forsberg, H., Holst, J. J., Seckl, J. R., & Ahren, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460397 · Cited by 13
Elrishi, M., Khunti, K., Jarvis, J., & Davies, M. (2007) · Practical Diabetes · doi:10.1002/pdi.1181 · Cited by 15
Glucagon‐like peptide‐1 in type 2 diabetes: the β‐cell and beyond
Nauck, M. A. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00919.x · Cited by 14
Self-citationLiraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus
Joffe, D. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090230 · Cited by 15
Higher endogenous glucose production during OGTT vs isoglycemic intravenous glucose infusion
Lund, A., Bagger, J. I., Christensen, M., Grøndahl, M., van Hall, G., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1948 · Cited by 12
Mahmoudi, A. A., Rostami, M., Hajihasani, M. M., Sukhorukov, V. N., Kesharwani, P., & Sahebkar, A. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.112866 · Cited by 13
Douros, J. D., Mowery, S. A., & Knerr, P. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113812 · Cited by 12
“Exogenous GIP-potentiated insulin secretion is nearly ablated in patients with T2D [8,9].”
Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
Singh, A. K. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.146881 · Cited by 13
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
van Baar, A. C. G., Meiring, S., Holleman, F., Hopkins, D., Mingrone, G., Deviere, J. M. E., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2021) · Gut · doi:10.1136/gutjnl-2020-323931 · Cited by 13
The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
Green, J. B. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2566 · Cited by 13
“The Incretin System in T2DM Patients with T2DM have a blunted incretin effect—they secrete significantly less insulin than healthy individuals in response to glucose, with the difference in response to oral glucose being most dramatic when compared with controls, as shown in Figure 1B.(13) Although patients with T2DM…”
ResultNotsu, M., Kanazawa, I., Tanaka, S., Yamaguchi, T., & Sugimoto, T. (2015) · Clinical Endocrinology · doi:10.1111/cen.12971 · Cited by 12
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 14
“fully appreciate its significance and another 2 decades to translate the discovery into pharmacological and clinical significance.(3) The”
BackgroundIncretin Physiology and Pharmacology in the Intensive Care Unit
Plummer, M. P., Hermanides, J., & Deane, A. M. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.011 · Cited by 12
The incretin effect does not differ in trained and untrained, young, healthy men
Lund, M. T., Dalby, S., Hartmann, B., Helge, J. W., Holst, J. J., & Dela, F. (2014) · Acta Physiologica · doi:10.1111/apha.12218 · Cited by 12
“A lower insulin clearance during an OGTT compared with an IIGI has previously been shown in patients with type 2 diabetes and obese subjects (Nauck et al. 1986b, Shuster et al. 1988, Meier et al. 2007).”
BackgroundMethodResultInfluentialChen, C., & Sibley, E. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00314.2011 · Cited by 12
Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
Robertson, C. (2011) · Diabetes Spectrum · doi:10.2337/diaspect.24.1.26 · Cited by 14
Lo, M. C., & Lansang, M. C. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ec9eb2 · Cited by 15
García‐Casares, N., García-Arnés, J. A., Gómez‐Huelgas, R., Valdivielso, P., García-Arias, C., & González‐Santos, P. (2014) · Revista de Neurología · doi:10.33588/rn.5911.2014023 · Cited by 16
Musso, G., Pinach, S., Saba, F., Michieli, F. D., Cassader, M., & Gambino, R. (2024) · Med · doi:10.1016/j.medj.2024.03.014 · Cited by 13
α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion
Cui, C., Leander, D. C., Gray, S. M., EL, K. M., Chen, A. Y., Grimsrud, P. A., Becker, J. O., Taylor, A. J., Zhang, G., Sloop, K. W., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady8048 · Cited by 15
“This effect is impaired among people with type 2 diabetes and partially explains their insufficient insulin secretion ( 4 ).”
Murao, N., Seino, Y., Morikawa, R., Hidaka, S., Haraguchi, T., Tomatsu, E., Habara, M., Ohno, T., Yokoi, N., Harada, N., et al. (2025) · The Journal of Physiology · doi:10.1113/jp289067 · Cited by 11
“Collectively, the incretin– β -cell axis is critical for glucose homeostasis (Nauck et al., 1986; Nauck & Meier, 2016).”
Abraham, K. A., Kearney, M. L., Reynolds, L. J., & Thyfault, J. P. (2015) · Diabetology International · doi:10.1007/s13340-015-0234-y · Cited by 12
“However, their use of intravenous glucose tolerance tests is problematic, because GLP-1 release is not stimulated by infused glucose [21]; thus, there can be little meaningful comparison between the current investigation and that of Svartberg et al.”
ResultSwedberg, J. E., Schroeder, C. I., Mitchell, J. M., Fairlie, D. P., Edmonds, D. J., Griffith, D. A., Ruggeri, R. B., Derksen, D. R., Loria, P. M., Price, D. A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.724542 · Cited by 15
“The incretin effect is often greatly reduced in patients suffering from type 2 diabetes mellitus (4), and a possible therapeutic approach for this condition is incretin supplement therapy.”
BackgroundThe Effects of Diabetes and Diabetic Medications on Bone Health
Elamir, Y. M., Gianakos, A. L., Lane, J. M., Sharma, A., Grist, W., Liporace, F. A., & Yoon, R. S. (2019) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001635 · Cited by 11
Gléau, L. L., Rouault, C., Osinski, C., Prifti, E., Soula, H. A., Debédat, J., Busieau, P., Amouyal, C., Clément, K., Andréelli, F., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00071.2021 · Cited by 19
Remission of Type 2 Diabetes Mellitus by Ileal Interposition with Sleeve gastrectomy
Kota, S. K., Ugale, S. M., Gupta, N., Naik, V., Kota, S. K., Kumar, K. H., & Modi, K. D. (2012) · Intern J Endocrinol Metab · doi:10.5812/kowsar.1726913x.2782 · Cited by 12
Muscelli, E., Frascerra, S., Casolaro, A., Baldi, S., Mari, A., Gall, W., Cobb, J., & Ferrannini, E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12350 · Cited by 11
Pharmacogenetic Aspects of the Treatment of Type 2 Diabetes with the Incretin Effect Enhancers
Tkáč, I., & Gotthardová, I. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0011 · Cited by 11
GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
Nomiyama, T., & Yanase, T. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1191349 · Cited by 14
Barale, C., Frascaroli, C., Cavalot, F. L., & Russo, I. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.06.010 · Cited by 12
Marathe, C. S., Pham, H., Marathe, J., Trahair, L. G., Huynh, L. Q., Wu, T., Phillips, L. K., Rayner, C. K., Nauck, M. A., Horowitz, M., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01461-z · Cited by 11
Self-citationEarly clinical studies with liraglutide
Schmidt, W. E. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02500.x · Cited by 13
García-Martínez, J. M., Chocarro‐Calvo, A., la Vieja, A. D., & García‐Jiménez, C. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.07.020 · Cited by 11
Rita, R. S., Dezaki, K., Kurashina, T., Kakei, M., & Yada, T. (2014) · Endocrinology · doi:10.1210/en.2014-1728 · Cited by 12
Insulin Contributes to Fine-Tuning of the Pancreatic Beta-Cell Response to Glucagon-Like Peptide-1
Moon, M. J., Kim, H. Y., Park, S., Kim, D.-K., Cho, E. B., Hwang, J., & Seong, J. Y. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0157-9 · Cited by 11
Suh, S., Kim, M. Y., Kim, S. K., Hur, K. Y., Park, M. K., Kim, D. K., Cho, N. H., & Lee, M. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.134 · Cited by 11
The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
Åhrén, B., Yamada, Y., & Seino, Y. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz036 · Cited by 12
“Moreover, it has been estimated that approximately 70% of insulin secretion after oral glucose is dependent on the incretin effect in humans (9, 10).”
BackgroundResultTorre, E., Bruno, G. M., Matteo, S. D., Martinotti, C., Valentino, M. C., Bottaro, L. C., & Colombo, G. L. (2020) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s240183 · Cited by 11
Pathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 13
Schwanstecher, C., & Schwanstecher, M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_1 · Cited by 13
Opioid Blockade Effect on Insulin β-Cells Secretory Patterns in Polycystic Ovary Syndrome
Ciampelli, M., Fulghesu, A. M., Guido, M., Murgia, F., Muzj, G., Belosi, C., Fortini, A., Cento, R. M., & Lanzone, A. (1998) · Hormone Research in Paediatrics · doi:10.1159/000023185 · Cited by 11
Meece, J. D. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0491-1 · Cited by 16
Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor
Zhang, Z., Pan, H., Guo, L., Cai, C., Chen, T., Zhang, Z., Xu, Y., Zheng, H., Jiang, C., Wang, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01177 · Cited by 10
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits
Hwang, E., Portillo, B., & Williams, K. W. (2025) · Endocrinology · doi:10.1210/endocr/bqaf125 · Cited by 10
Synthesis and Evaluation of Optical and PET GLP-1 Peptide Analogues for GLP-1R Imaging
Azad, B. B., Rota, V., Yu, L., McGirr, R., Amant, A. H. S., Lee, T.-Y., Dhanvantari, S., & Luyt, L. G. (2015) · Molecular Imaging · doi:10.2310/7290.2014.00057 · Cited by 10
“labeled GLP-1(7-37) peptides in CD1 and C57BL/6 mice.”
BackgroundMethodVMP1-related autophagy induced by a fructose-rich diet in β-cells: its prevention by incretins
Maiztegui, B., Boggio, V., Román, C. L., Flores, L. E., Zotto, H. H. D., Ropolo, A., Grasso, D., Vaccaro, M. I., & Gagliardino, J. J. (2017) · Clinical Science · doi:10.1042/cs20170010 · Cited by 12
Chakraborty, S., Rendón-Ramírez, A., Ásgeirsson, B., Dutta, M., Ghosh, A. S., Oda, M., Venkatramani, R., Rao, B. J., Dandekar, A. M., & Goñi, F. M. (2013) · F1000Research · doi:10.12688/f1000research.2-286.v1 · Cited by 13
Subramanian, V., Bagger, J. I., Harihar, V., Holst, J. J., Knop, F. K., & Villsbøll, T. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00278.2023 · Cited by 12
Diabetes, incretin hormones and cardioprotection
Myat, A., Redwood, S. R., Gersh, B. J., Yellon, D. M., & Marber, M. S. (2014) · Heart · doi:10.1136/heartjnl-2012-303242 · Cited by 11
Recovery of the Incretin Effect in Type 2 Diabetic Patients After Biliopancreatic Diversion
Novaes, F. S., Vasques, A. C. J., Pareja, J. C., Knop, F. K., Tura, A., Chaim, É. A., & Geloneze, B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4042 · Cited by 11
Grunberger, G. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1727-5 · Cited by 10
“Once studies confirmed presence of an “incretin defect” among patients with T2DM [12], investigators focused on enhancing the “incretin effect” pharmacologically.”
BackgroundKim, M., Oh, T. J., Lee, J. C., Choi, K., Kim, H. C., Kim, S., Cho, Y. M., & Kim, S. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.3.378 · Cited by 11
“Furthermore, the incretin hormones have been recognized as a major insulin secretory stimulus after an oral glucose load (1, 3, 4); and several models that include the incretin concept have been developed to describe the glucose dynamics during the OGTT in a more physiologic manner (10, 13-15).”
BackgroundResultInfluentialAssessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
Sjöstrand, M., Wei, C., Cook, W., Johnsson, K. M., Pollack, P. S., Stahre, C., & Hirshberg, B. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0261-8 · Cited by 10
“Inhibition of DPP-4 prevents the degradation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), two gastrointestinal-derived hormones that play major roles in blood glucose control [22].”
BackgroundInfluentialEfficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus
Orime, K., & Terauchi, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1803280 · Cited by 13
Hunt, J. E., Holst, J. J., & Jepsen, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884501 · Cited by 12
“98170-4), and (125)I-labeled human GIP(1-42) tracer (cat.”
MethodDesign, findings and implications of the liraglutide Phase III clinical trial program
Bode, B. W. (2011) · Clinical Investigation · doi:10.4155/cli.11.166 · Cited by 10
Anagnostis, P. G., Siolos, P., Christou, K., Gkekas, N. K., Kosmidou, N., Athyros, V. G., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0017-5 · Cited by 10
The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
Nilsson, M. S. D., Bove, K. B., Suhrs, H. E., Hermann, T. S., Madsbad, S., Holst, J. J., Prescott, E., & Zander, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.01.004 · Cited by 10
“Differences in GLP-1 secretion and action between healthy subjects, obese subjects and patients with type 2 diabetes have formerly been documented [39,40].”
Background
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.